REPL

Replimune Group

• Seeking Alpha·19h ago

  Replimune plans layoffs as FDA rejects cancer drug

• Reuters·1d ago

  BUZZ-Replimune tumbles after FDA declines to approve melanoma drug

• Dow Jones·1d ago

  Replimune Disputes FDA Rejection of Skin Cancer Treatment, Criticizes Review Process

• TipRanks·1d ago

  Replimune downgraded to Underperform from Market Perform at BMO Capital

• Benzinga·1d ago

  Replimune Group Obtains Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma; Co. Says Disagrees With FDA About Whether RP1 BLA Data Set Is Enough To Allow The Medicine To Be Made Available To Advanced Cancer Patients; Says We Have No Choice But To Eliminate Jobs, Including Substantially Scaling Back U.S.-Based Manufacturing Operations

• TipRanks·1d ago

  Replimune says FDA’s CRL for RP1 ‘disappointing’

• TipRanks·1d ago

  Replimune says FDA ‘appears to have contradicted their positions’ in CRL

• Reuters·1d ago

  REPLIMUNE: BASED ON FDA FEEDBACK, STARTED IGNYTE-3 TO SATISFY REGULATORY REQUIREMENT THAT CONFIRMATORY STUDY BE UNDERWAY FOR ACCELERATED APPROVAL

• Reuters·1d ago

  FDA issues complete response letter for Replimune RP1 melanoma BLA

• TipRanks·1d ago

  Replimune downgraded to Neutral from Overweight at Cantor Fitzgerald

• TipRanks·1d ago

  Replimune downgraded to Neutral at Piper Sandler after second CRL

• TipRanks·1d ago

  Replimune downgraded to Neutral from Overweight at Piper Sandler

• Seeking Alpha·1d ago

  Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives

• Benzinga·1d ago

  FDA Again Rejects Replimune Skin Cancer Therapy, Says Evidence Falls Short

• TipRanks·1d ago

  Replimune CRL positive for Iovance in near-term, says Chardan